PONTE VEDRA, Fla., Aug. 6, 2024 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart...
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
Consumer Health Wind Down and Sale Maximizes Shareholder Value as Company Focuses on Rx SegmentEliminates Materially All Remaining Expenses Associated with the Consumer Health BusinessProvides for Receipt of Future Sales-Based Royalty Payments DENVER, CO / August 6,...
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
Encinitas, California--(August 6, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming conferences that will be available to investors by live webcast. On Tuesday August 13th, 2024 at 3:00 pm Eastern...
InfuSystem Announces Distribution Agreement with Smith+Nephew for Negative Pressure Wound Therapy System and First Shipment of NPWT Systems
ROCHESTER HILLS, Mich. - InfuSystem Holdings, Inc. (NYSE American: INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced...
Delcath Systems Reports Second Quarter 2024 Results and Business Highlights
Company Reports $7.8 million in Quarterly Revenue Conference Call Today at 4:30pm Eastern Time QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic...
NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024
CARMEL, Ind., Aug. 05, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized...
Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced today that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-on...
Dror Ortho-Design, Inc. Launches ZSMILE User Experience Trial
JERUSALEM, Aug. 05, 2024 -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people's smiles by straightening teeth using pulsating air delivered by a...
InfuSystem to Report Second Quarter 2024 Financial Results on August 8, 2024
Investor Conference Call to be held 9:00 a.m. Eastern Time ROCHESTER HILLS, Mich. - InfuSystem Holdings, Inc. (NYSE American: INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical...
Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience
-Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over year growth- -Reiterating financial guidance of approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of...